CN117881421A - 用于刺激免疫活性的方法和组合物 - Google Patents

用于刺激免疫活性的方法和组合物 Download PDF

Info

Publication number
CN117881421A
CN117881421A CN202280059679.4A CN202280059679A CN117881421A CN 117881421 A CN117881421 A CN 117881421A CN 202280059679 A CN202280059679 A CN 202280059679A CN 117881421 A CN117881421 A CN 117881421A
Authority
CN
China
Prior art keywords
antigen binding
antigen
receptor
cell
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280059679.4A
Other languages
English (en)
Chinese (zh)
Inventor
P·施莱格尔
A·乔奇纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosceptre Ausi Pty Ltd
Original Assignee
Biosceptre Ausi Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021902832A external-priority patent/AU2021902832A0/en
Application filed by Biosceptre Ausi Pty Ltd filed Critical Biosceptre Ausi Pty Ltd
Publication of CN117881421A publication Critical patent/CN117881421A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
CN202280059679.4A 2021-09-01 2022-09-01 用于刺激免疫活性的方法和组合物 Pending CN117881421A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021902832 2021-09-01
AU2021902832A AU2021902832A0 (en) 2021-09-01 Methods and compositions for stimulating immune activity
PCT/AU2022/051070 WO2023028657A1 (en) 2021-09-01 2022-09-01 Methods and compositions for stimulating immune activity

Publications (1)

Publication Number Publication Date
CN117881421A true CN117881421A (zh) 2024-04-12

Family

ID=85410590

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202280059679.4A Pending CN117881421A (zh) 2021-09-01 2022-09-01 用于刺激免疫活性的方法和组合物
CN202280053364.9A Pending CN117813109A (zh) 2021-09-01 2022-09-01 新型功能障碍p2x7结合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202280053364.9A Pending CN117813109A (zh) 2021-09-01 2022-09-01 新型功能障碍p2x7结合物

Country Status (8)

Country Link
US (2) US20240368282A1 (https=)
EP (2) EP4395813A4 (https=)
JP (2) JP2024532482A (https=)
CN (2) CN117881421A (https=)
AU (2) AU2022335932A1 (https=)
CA (2) CA3223079A1 (https=)
MX (2) MX2023015469A (https=)
WO (2) WO2023028657A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3240805T3 (fi) * 2014-12-15 2025-02-17 Univ California Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori
US20220267450A1 (en) * 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
EP4384219A4 (en) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
AU2024232401A1 (en) * 2023-03-08 2025-08-21 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors for binding to dysfunctional p2x 7 receptor
WO2024211413A2 (en) * 2023-04-05 2024-10-10 Arizona Board Of Regents On Behalf Of The University Of Arizona Trogocytosis in cancer cells and methods for treating cancer related thereto
WO2024220870A1 (en) * 2023-04-19 2024-10-24 The University Of Chicago Antibody-targeted enzymatic chemoprotection
AU2024269870A1 (en) * 2023-05-05 2025-11-20 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells
EP4735479A1 (en) * 2023-06-30 2026-05-06 Biosceptre (Aust) Pty Ltd Molecules and methods for activating car t cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2467404B1 (en) * 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) * 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
US20180037650A1 (en) * 2015-04-02 2018-02-08 Biosceptre (Uk) Limited Pain Treatment
US12121539B2 (en) * 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
MX2019004410A (es) * 2016-10-21 2019-09-26 Biosceptre Uk Ltd Particulas citotoxicas.
CN112166193A (zh) * 2018-05-21 2021-01-01 生物权威（英国）有限公司 具有经修饰的接头结构域的嵌合抗原受体及其用途
US20220177583A1 (en) * 2019-03-20 2022-06-09 The Regents Of The University Of California Claudin-6 bispecific antibodies
CN113853388B (zh) * 2019-03-27 2024-07-19 加拿大国家研究委员会 抗-egfrviii抗体及其抗原结合片段
EP4304610A4 (en) * 2021-03-11 2025-03-05 Biosceptre (Aust) Pty Ltd Novel cell therapy system

Also Published As

Publication number Publication date
CA3223079A1 (en) 2023-03-09
WO2023028657A1 (en) 2023-03-09
AU2022335932A1 (en) 2023-11-30
JP2024532482A (ja) 2024-09-05
MX2023015469A (es) 2024-01-19
JP2024532489A (ja) 2024-09-05
CN117813109A (zh) 2024-04-02
EP4395814A1 (en) 2024-07-10
CA3223086A1 (en) 2023-03-09
US20240368282A1 (en) 2024-11-07
AU2022341030A1 (en) 2023-11-30
MX2023015028A (es) 2024-02-16
EP4395813A1 (en) 2024-07-10
EP4395813A4 (en) 2025-07-09
WO2023028653A1 (en) 2023-03-09
US20240376193A1 (en) 2024-11-14
EP4395814A4 (en) 2025-09-03

Similar Documents

Publication Publication Date Title
CN117881421A (zh) 用于刺激免疫活性的方法和组合物
KR102387243B1 (ko) 트랜스진 유전자 태그 및 사용 방법
EP3442567B1 (en) Anti-psma antibodies and use thereof
JP2021534762A (ja) 抗メソテリンキメラ抗原受容体（ｃａｒ）構築物及びその使用
US20250281611A1 (en) Novel cell therapy system
US20230149460A1 (en) Methods for generating engineered memory-like nk cells and compositions thereof
EP4119578A1 (en) Bcma-specific antibody and chimeric antigen receptor
TW202432828A (zh) Ａｄｇｒｅ２嵌合受體ｎｋ細胞組成物及使用方法
WO2023138666A1 (en) Circular rna and use thereof
KR20250067130A (ko) Mage-a4 펩티드 이중 t 세포 연결체
WO2025140265A1 (en) Combination of chimeric antigen receptor and dap10 in cell therapy
US20260061051A1 (en) Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
IL305181A (en) Cell therapy compositions and methods for modulating tgf-b signaling
CN117750963A (zh) 新的细胞疗法系统
CN121263439A (zh) 用于激活car-t细胞的分子和方法
WO2025072871A2 (en) ANTI-SIRPα ANTIBODY COMPOSITIONS AND USES THEREOF
WO2023078431A1 (zh) 一种特异性结合间皮素的合成t细胞受体抗原受体及其应用
WO2025184421A1 (en) Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
HK40128378A (zh) 对δ样配体3(DLL3)具有特异性的抗体和嵌合抗原受体
CN121127259A (zh) 用于结合功能障碍的p2x7受体的嵌合抗原受体
CN113528560A (zh) 靶向白蛋白的嵌合抗原受体及其使用方法
HK40056378B (zh) 人源化抗claudin18.2嵌合抗原受体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination